TRIP13 and plasma cell myeloma: Our results indicated that overexpression of TRIP13 led to decreased apoptosis and conferred protection against drug-induced cytotoxicity in myeloma cells when treated with increasing doses of Bortezomib (5–20 nM) (Figure 2E, p < 0.05).